Literature DB >> 8205825

Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension.

D L Wessel1, I Adatia, J E Thompson, P R Hickey.   

Abstract

OBJECTIVE: The development of a safe, portable, accurate, and adaptable system to deliver nitric oxide to patients with pulmonary hypertension.
DESIGN: A prospective, clinical study.
SETTING: Tertiary care pediatric intensive care unit and cardiac catheterization laboratory. PATIENTS: One hundred twenty-three patients (median age 11 months, range 1 day to 72 yrs) with pulmonary hypertension who were administered nitric oxide between November 1991 and July 1993. Ninety-one patients were mechanically ventilated (volume-controlled ventilator, n = 53; pressure-controlled ventilator, n = 5; and a pressure-limited, time-cycled infant ventilator, n = 25). The system was adapted to allow high-frequency oscillator (n = 2) or hand ventilation, and for intraoperative use with an anesthesia machine (n = 6). Thirty-two patients were breathing spontaneously through a mask without assistance.
INTERVENTIONS: Nitric oxide was delivered at 10 to 80 parts per million (ppm); the dose was adjusted independently of the FIO2 without altering minute ventilation or tidal volume.
MEASUREMENTS AND MAIN RESULTS: Nitrogen dioxide was continuously monitored and exceeded 3 ppm in only four patients. Methemoglobin concentrations were < 5% in all but four patients. Nitric oxide doses remained stable, independent of minute ventilation and could be changed easily and quickly.
CONCLUSIONS: Inhaled nitric oxide can be administered precisely and reliably through a variety of delivery systems which can be used in patients of any size. Potential toxicity requires careful monitoring and continued improvement on apparatus design.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8205825     DOI: 10.1097/00003246-199406000-00009

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  23 in total

1.  Pulmonary uptake and modes of administration of inhaled nitric oxide in mechanically-ventilated patients.

Authors: 
Journal:  Crit Care       Date:  1998       Impact factor: 9.097

2.  Eisenmenger's Syndrome.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-12

3.  Inhaled nitric oxide fraction is influenced by both the site and the mode of administration.

Authors:  E Sieffert; L Ducros; M R Losser; D M Payen
Journal:  J Clin Monit Comput       Date:  1999-12       Impact factor: 2.502

4.  Inhaled nitric oxide delivery and monitoring.

Authors:  F J Montgomery; A D Berssenbrugge
Journal:  J Clin Monit Comput       Date:  1999-07       Impact factor: 2.502

5.  Use of nitric oxide inhalation in chronic obstructive pulmonary disease.

Authors:  K Ashutosh; K Phadke; J F Jackson; D Steele
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

6.  Occupational exposure during nitric oxide inhalational therapy in a pediatric intensive care setting.

Authors:  D G Markhorst; T Leenhoven; J W Uiterwijk; J Meulenbelt; A J van Vught
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

7.  Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system.

Authors:  O H Frazier; E A Rose; P McCarthy; N A Burton; A Tector; H Levin; H L Kayne; V L Poirier; K A Dasse
Journal:  Ann Surg       Date:  1995-09       Impact factor: 12.969

8.  A European survey of the use of inhaled nitric oxide in the ICU. Working Group on Inhaled NO in the ICU of the European Society of Intensive Care Medicine.

Authors:  S Beloucif; D Payen
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

Review 9.  Delivery and monitoring of inhaled nitric oxide.

Authors:  J D Young; O J Dyar
Journal:  Intensive Care Med       Date:  1996-01       Impact factor: 17.440

10.  Changes in alveolar-arterial oxygen difference and oxygenation index during low-dose nitric oxide inhalation in 15 newborns with severe respiratory insufficiency.

Authors:  Z Stranák; V Zábrodský; J Simák
Journal:  Eur J Pediatr       Date:  1996-10       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.